Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC

Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauvin, Camille, Krishnan, Vimal, Kaci, Imane, Tran-Thanh, Danh, Bédard, Karine, Albadine, Roula, Leduc, Charles, Gaboury, Louis, Blais, Normand, Tehfe, Mustapha, Routy, Bertrand, Florescu, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924378/
https://www.ncbi.nlm.nih.gov/pubmed/33498159
http://dx.doi.org/10.3390/curroncol28010059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924378/
https://www.ncbi.nlm.nih.gov/pubmed/33498159
http://dx.doi.org/10.3390/curroncol28010059

Ejemplares similares